30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Avalo Therapeutics Inc (AVTX)

Track

Over the last 90 days, Avalo Therapeutics Inc. has seen significant insider selling, with a net value of -$411,606. Notable transactions include proposed and planned sales by directors and officers, totaling over $12.5 million in sell volume. There were no insider purchases recorded during this period. The stock has experienced a 7.9% price decrease over the same timeframe.
Stock chart
Ticker: AVTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Doyle Mittie
Chief Medical Officer
1 sale — total 100,000 USD
Planned sale 23 Jun 2026
Value US$1,182,222.61 | Price 74.68 | Shares 76,824
Proposed sale 2 Jun 2026
Value US$2,653,655.94 | Price 161.55 | Shares 96,429
Planned sale 28 May 2026
Value US$10,864.00 | Price 16.00 | Shares 679
Planned sale 15 May 2026
Value US$56,280.00 | Price 18.76 | Shares 3,000
Planned sale 7 May 2026
Value US$448,817.65 | Price 24.12 | Shares 18,606
Proposed sale 7 May 2026
Value US$405,796.86 | Price 21.81 | Shares 18,606
Planned sale 6 May 2026
Value US$9,484.00 | Price 23.71 | Shares 400
Planned sale 6 May 2026
Value US$210,029.22 | Price 22.70 | Shares 9,253
Planned sale 6 May 2026
Value US$484,540.80 | Price 21.22 | Shares 22,839
Planned sale 6 May 2026
Value US$102,783.12 | Price 19.78 | Shares 5,196
Planned sale 6 May 2026
Value US$706,836.00 | Price 18.91 | Shares 37,375
Planned sale 6 May 2026
Value US$200,913.05 | Price 22.57 | Shares 8,900
Planned sale 6 May 2026
Value US$197,008.19 | Price 21.37 | Shares 9,219
Planned sale 6 May 2026
Value US$56,052.00 | Price 20.76 | Shares 2,700
Planned sale 6 May 2026
Value US$238,093.37 | Price 19.28 | Shares 12,347
Planned sale 6 May 2026
Value US$256,655.28 | Price 18.55 | Shares 13,834
Planned sale 6 May 2026
Value US$230,127.04 | Price 22.88 | Shares 10,058
Planned sale 6 May 2026
Value US$426,050.09 | Price 22.41 | Shares 19,015
Planned sale 6 May 2026
Value US$952,668.98 | Price 21.20 | Shares 44,944
Planned sale 6 May 2026
Value US$98,251.00 | Price 19.65 | Shares 5,000
Planned sale 6 May 2026
Value US$496,405.50 | Price 18.03 | Shares 27,538
Planned sale 6 May 2026
Value US$72,460.96 | Price 22.88 | Shares 3,167
Proposed sale 6 May 2026
Value US$886,300.08 | Price 16.26 | Shares 54,508
Proposed sale 6 May 2026
Value US$764,220.00 | Price 16.26 | Shares 47,000
Proposed sale 6 May 2026
Value US$1,508,456.46 | Price 16.26 | Shares 92,771
Proposed sale 6 May 2026
Value US$51,495.42 | Price 16.26 | Shares 3,167
Planned sale 5 May 2026
Value US$26,864.00 | Price 16.00 | Shares 1,679
Planned sale 30 Apr 2026
Value US$111,853.13 | Price 13.23 | Shares 8,457
Planned sale 29 Apr 2026
Value US$110,736.36 | Price 13.09 | Shares 8,458
Proposed sale 29 Apr 2026
Value US$217,526.90 | Price 12.86 | Shares 16,915
Planned sale 6 Apr 2026
Value US$71,508.43 | Price 18.01 | Shares 3,970
Proposed sale 6 Apr 2026
Value US$1,168,608.00 | Price 17.76 | Shares 65,800
Planned sale 2 Apr 2026
Value US$31,269.97 | Price 17.57 | Shares 1,780
Planned sale 2 Apr 2026
Value US$105,553.14 | Price 17.02 | Shares 6,200
Planned sale 1 Apr 2026
Value US$125,840.91 | Price 16.83 | Shares 7,479
Planned sale 1 Apr 2026
Value US$7,929.00 | Price 15.86 | Shares 500
Planned sale 1 Apr 2026
Value US$10,864.00 | Price 16.00 | Shares 679
Proposed sale 1 Apr 2026
Value US$238,267.87 | Price 14.93 | Shares 15,959
Sale 16 Mar 2026
Value US$411,606.58 | Price 16.15 | Shares 25,492
Proposed sale 16 Mar 2026
Value US$466,558.20 | Price 15.80 | Shares 29,529
Sale 14 Nov 2025
Value US$117,648.68 | Price 14.35 | Shares 8,200
Sale 14 Nov 2025
Value US$45,288.10 | Price 14.30 | Shares 3,167
Buy 13 Nov 2024
Value US$6,500.00 | Price 13.00 | Shares 500
Buy 12 Nov 2024
Value US$6,249.50 | Price 12.50 | Shares 500
Sale 27 Jun 2023
Value US$486,887.64 | Price 0.52 | Shares 937,404
Sale 26 Jun 2023
Value US$1,682,009.52 | Price 0.61 | Shares 2,746,138
Buy 20 Jun 2023
Value US$8,288.80 | Price 4.14 | Shares 2,000
Buy 16 Jun 2023
Value US$11,714.40 | Price 3.90 | Shares 3,000
Buy 15 Jun 2023
Value US$11,640.49 | Price 3.68 | Shares 3,160
Buy 14 Jun 2023
Value US$20,874.00 | Price 3.48 | Shares 6,000
Buy 13 Jun 2023
Value US$33,439.00 | Price 3.82 | Shares 8,750
Buy 12 Jun 2023
Value US$9,316.34 | Price 4.34 | Shares 2,149
Planned buy 9 Jun 2023
Value US$13,680.00 | Price 3.42 | Shares 4,000
Planned buy 9 Jun 2023
Value US$1,747.62 | Price 3.42 | Shares 511
Buy 9 Jun 2023
Value US$20,895.78 | Price 4.14 | Shares 5,044
Buy 8 Jun 2023
Value US$25,125.59 | Price 3.93 | Shares 6,398
Buy 7 Jun 2023
Value US$10,418.34 | Price 3.49 | Shares 2,984
Buy 31 May 2023
Value US$2,422.28 | Price 2.87 | Shares 844
Buy 30 May 2023
Value US$1,923.76 | Price 2.87 | Shares 671
Buy 25 May 2023
Value US$5,540.00 | Price 2.77 | Shares 2,000
Buy 24 May 2023
Value US$16,348.38 | Price 2.96 | Shares 5,519
Buy 24 May 2023
Value US$10,468.06 | Price 3.01 | Shares 3,481
Buy 22 May 2023
Value US$23,357.60 | Price 3.34 | Shares 7,000
Buy 19 May 2023
Value US$22,852.05 | Price 3.52 | Shares 6,500
Buy 18 May 2023
Value US$43,162.84 | Price 3.29 | Shares 13,121
Buy 16 May 2023
Value US$1,042.25 | Price 2.75 | Shares 379
Buy 15 May 2023
Value US$4,366.22 | Price 2.55 | Shares 1,715
Buy 12 May 2023
Value US$5,598.25 | Price 2.45 | Shares 2,285
Buy 8 May 2023
Value US$13,108.00 | Price 2.62 | Shares 5,000
Buy 5 May 2023
Value US$14,375.00 | Price 2.88 | Shares 5,000
Buy 4 May 2023
Value US$41,881.50 | Price 2.79 | Shares 15,000
Buy 27 Apr 2023
Value US$4,451.84 | Price 2.96 | Shares 1,504
Buy 26 Apr 2023
Value US$1,262.25 | Price 2.97 | Shares 425
Buy 25 Apr 2023
Value US$16,709.10 | Price 3.00 | Shares 5,571
Buy 24 Apr 2023
Value US$38,280.00 | Price 3.06 | Shares 12,500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-25 2026-06-23 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
76,824 +8.4%
74.68
US$1,182,223 		76,824 +8.4% 74.68 US$1,182,223
2026-06-02 2026-06-02 PrS Proposed sale
0.8
JONATHAN GOLDMAN

Director

Non-Executive Director
96,429
161.55
US$2,653,656 		96,429 161.55 US$2,653,656
2026-06-01 2026-05-28 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
32,540 -12.5%
333.44
US$2,134,399 		32,540 -12.5% 333.44 US$2,134,399
2026-05-19 2026-05-15 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
3,000 -45.3%
18.76
US$56,280 		3,000 -45.3% 18.76 US$56,280
2026-05-11 2026-05-07 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
18,606 -97.8%
24.12
US$448,818 		18,606 -97.8% 24.12 US$448,818
2026-05-07 2026-05-07 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
18,606
21.81
US$405,797 		18,606 21.81 US$405,797
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
400 -9.9%
23.71
US$9,484 		400 -9.9% 23.71 US$9,484
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
9,253 -69.6%
22.70
US$210,029 		9,253 -69.6% 22.70 US$210,029
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
22,839 -63.2%
21.22
US$484,541 		22,839 -63.2% 21.22 US$484,541
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
5,196 -12.6%
19.78
US$102,783 		5,196 -12.6% 19.78 US$102,783
2026-05-07 2026-05-06 PlS Planned sale
VARKI PAUL

Chief Legal Officer

Officer
37,375 -47.5%
18.91
US$706,836 		37,375 -47.5% 18.91 US$706,836
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
8,900 -95.5%
22.57
US$200,913 		8,900 -95.5% 22.57 US$200,913
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
9,219 -49.7%
21.37
US$197,008 		9,219 -49.7% 21.37 US$197,008
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
2,700 -12.7%
20.76
US$56,052 		2,700 -12.7% 20.76 US$56,052
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
12,347 -36.8%
19.28
US$238,093 		12,347 -36.8% 19.28 US$238,093
2026-05-07 2026-05-06 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
13,834 -29.2%
18.55
US$256,655 		13,834 -29.2% 18.55 US$256,655
2026-05-07 2026-05-06 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
10,058 -73.5%
22.88
US$230,127 		10,058 -73.5% 22.88 US$230,127
2026-05-07 2026-05-06 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
19,015 -58.2%
22.41
US$426,050 		19,015 -58.2% 22.41 US$426,050
2026-05-07 2026-05-06 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
44,944 -57.9%
21.20
US$952,669 		44,944 -57.9% 21.20 US$952,669
2026-05-07 2026-05-06 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
5,000 -6.1%
19.65
US$98,251 		5,000 -6.1% 19.65 US$98,251
2026-05-07 2026-05-06 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
27,538 -25.0%
18.03
US$496,405 		27,538 -25.0% 18.03 US$496,405
2026-05-07 2026-05-06 PlS Planned sale
Chan Mitchell
Non-Executive Director
3,167 -50.0%
22.88
US$72,461 		3,167 -50.0% 22.88 US$72,461
2026-05-06 2026-05-06 PrS Proposed sale
MITTIE DOYLE

Officer

Officer
54,508
16.26
US$886,300 		54,508 16.26 US$886,300
2026-05-06 2026-05-06 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
47,000
16.26
US$764,220 		47,000 16.26 US$764,220
2026-05-06 2026-05-06 PrS Proposed sale
PAUL VARKI

Officer

Officer
92,771
16.26
US$1,508,456 		92,771 16.26 US$1,508,456
2026-05-06 2026-05-06 PrS Proposed sale
MITCHELL CHAN

Director

Non-Executive Director
3,167
16.26
US$51,495 		3,167 16.26 US$51,495
2026-05-07 2026-05-05 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
1,679 -31.7%
16.00
US$26,864 		1,679 -31.7% 16.00 US$26,864
2026-05-01 2026-04-30 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
8,457 -95.2%
13.23
US$111,853 		8,457 -95.2% 13.23 US$111,853
2026-05-01 2026-04-29 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
8,458 -48.8%
13.09
US$110,736 		8,458 -48.8% 13.09 US$110,736
2026-04-29 2026-04-29 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
16,915
12.86
US$217,527 		16,915 12.86 US$217,527
2026-04-08 2026-04-06 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
3,970 -52.3%
18.01
US$71,508 		3,970 -52.3% 18.01 US$71,508
2026-04-06 2026-04-06 PrS Proposed sale
MITTIE DOYLE

Officer

Officer
65,800
17.76
US$1,168,608 		65,800 17.76 US$1,168,608
2026-04-03 2026-04-02 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
1,780 -9.3%
17.57
US$31,270 		1,780 -9.3% 17.57 US$31,270
2026-04-03 2026-04-02 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
6,200 -24.5%
17.02
US$105,553 		6,200 -24.5% 17.02 US$105,553
2026-04-03 2026-04-01 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
7,479 -22.8%
16.83
US$125,841 		7,479 -22.8% 16.83 US$125,841
2026-04-03 2026-04-01 PlS Planned sale
Sullivan Christopher Ryan

Chief Financial Officer

Officer
500 -1.5%
15.86
US$7,929 		500 -1.5% 15.86 US$7,929
2026-04-03 2026-04-01 PlS Planned sale
Doyle Mittie

Chief Medical Officer

Officer
679 -15.8%
16.00
US$10,864 		679 -15.8% 16.00 US$10,864
2026-04-01 2026-04-01 PrS Proposed sale
CHRISTOPHER SULLIVAN

Officer

Officer
15,959
14.93
US$238,268 		15,959 14.93 US$238,268
2026-03-18 2026-03-16 S Sale
Doyle Mittie

Chief Medical Officer

Officer
25,492 -87.6%
16.15
US$411,607 		25,492 -87.6% 16.15 US$411,607
2026-03-16 2026-03-16 PrS Proposed sale
MITTIE DOYLE

Officer

Officer
29,529
15.80
US$466,558 		29,529 15.80 US$466,558
2025-11-17 2025-11-14 S Sale
0.8
Goldman Jonathan
Non-Executive Director
8,200 -100.0%
14.35
US$117,649 		8,200 -100.0% 14.35 US$117,649
2025-11-17 2025-11-14 S Sale
0.8
Goldman Jonathan
Non-Executive Director
3,167 -100.0%
14.30
US$45,288 		3,167 -100.0% 14.30 US$45,288
2024-11-14 2024-11-13 B Purchase
3.6
Almenoff June Sherie
Non-Executive Director
500 +100.0%
13.00
US$6,500 		500 +100.0% 13.00 US$6,500
2024-11-14 2024-11-12 B Purchase
3.6
Almenoff June Sherie
Non-Executive Director
500 +inf%
12.50
US$6,250 		500 +inf% 12.50 US$6,250
2023-06-28 2023-06-27 S Sale
2.5
ARMISTICE CAPITAL, LLC
Large shareholder
937,404 -56.2%
0.52
US$486,888 		937,404 -56.2% 0.52 US$486,888
2023-06-28 2023-06-26 S Sale
2.5
ARMISTICE CAPITAL, LLC
Large shareholder
2,746,138 -62.2%
0.61
US$1,682,010 		2,746,138 -62.2% 0.61 US$1,682,010
2023-06-20 2023-06-20 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,000 +0.1%
4.14
US$8,289 		2,000 +0.1% 4.14 US$8,289
2023-06-20 2023-06-16 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
3,000 +0.2%
3.90
US$11,714 		3,000 +0.2% 3.90 US$11,714
2023-06-20 2023-06-15 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
3,160 +0.2%
3.68
US$11,640 		3,160 +0.2% 3.68 US$11,640
2023-06-14 2023-06-14 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
6,000 +0.4%
3.48
US$20,874 		6,000 +0.4% 3.48 US$20,874
2023-06-14 2023-06-13 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
8,750 +0.6%
3.82
US$33,439 		8,750 +0.6% 3.82 US$33,439
2023-06-14 2023-06-12 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,149 +0.2%
4.34
US$9,316 		2,149 +0.2% 4.34 US$9,316
2023-06-13 2023-06-09 PP Planned purchase
NEIL GARRY ARTHUR

CEO and Chairman of the Board

Executive Director
4,000 +43.4%
3.42
US$13,680 		4,000 +43.4% 3.42 US$13,680
2023-06-13 2023-06-09 PP Planned purchase
Sullivan Christopher Ryan

Chief Financial Officer

Officer
511 +68.0%
3.42
US$1,748 		511 +68.0% 3.42 US$1,748
2023-06-09 2023-06-09 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
5,044 +0.4%
4.14
US$20,896 		5,044 +0.4% 4.14 US$20,896
2023-06-09 2023-06-08 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
6,398 +0.5%
3.93
US$25,126 		6,398 +0.5% 3.93 US$25,126
2023-06-09 2023-06-07 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,984 +0.2%
3.49
US$10,418 		2,984 +0.2% 3.49 US$10,418
2023-06-02 2023-05-31 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
844 +0.1%
2.87
US$2,422 		844 +0.1% 2.87 US$2,422
2023-05-30 2023-05-30 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
671 +0.0%
2.87
US$1,924 		671 +0.0% 2.87 US$1,924
2023-05-30 2023-05-25 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,000 +0.1%
2.77
US$5,540 		2,000 +0.1% 2.77 US$5,540
2023-05-24 2023-05-24 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
5,519 +0.4%
2.96
US$16,348 		5,519 +0.4% 2.96 US$16,348
2023-05-24 2023-05-24 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
3,481 +0.3%
3.01
US$10,468 		3,481 +0.3% 3.01 US$10,468
2023-05-22 2023-05-22 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
7,000 +0.5%
3.34
US$23,358 		7,000 +0.5% 3.34 US$23,358
2023-05-22 2023-05-19 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
6,500 +0.5%
3.52
US$22,852 		6,500 +0.5% 3.52 US$22,852
2023-05-22 2023-05-18 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
13,121 +1.0%
3.29
US$43,163 		13,121 +1.0% 3.29 US$43,163
2023-05-16 2023-05-16 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
379 +0.0%
2.75
US$1,042 		379 +0.0% 2.75 US$1,042
2023-05-16 2023-05-15 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
1,715 +0.1%
2.55
US$4,366 		1,715 +0.1% 2.55 US$4,366
2023-05-16 2023-05-12 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
2,285 +0.2%
2.45
US$5,598 		2,285 +0.2% 2.45 US$5,598
2023-05-08 2023-05-08 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
5,000 +0.4%
2.62
US$13,108 		5,000 +0.4% 2.62 US$13,108
2023-05-08 2023-05-05 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
5,000 +0.4%
2.88
US$14,375 		5,000 +0.4% 2.88 US$14,375
2023-05-08 2023-05-04 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
15,000 +1.1%
2.79
US$41,882 		15,000 +1.1% 2.79 US$41,882
2023-04-27 2023-04-27 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
1,504 +0.1%
2.96
US$4,452 		1,504 +0.1% 2.96 US$4,452
2023-04-27 2023-04-26 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
425 +0.0%
2.97
US$1,262 		425 +0.0% 2.97 US$1,262
2023-04-27 2023-04-25 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
5,571 +0.4%
3.00
US$16,709 		5,571 +0.4% 3.00 US$16,709
2023-04-24 2023-04-24 B Purchase
1.6
Caissa Capital Management ltd.
Large shareholder
12,500 +1.0%
3.06
US$38,280 		12,500 +1.0% 3.06 US$38,280
Explore more

More insider trading research around Avalo Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America